Complex Approach to the Management of Acneiform Rash Induced by Epidermal Growth Factor Receptor Inhibitors

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Rationale. Acneiform (papulopustular) rash is the leading dermatological adverse event of EGFR inhibitors. The development of optimal regimens for the supportive treatment of acneiform rash remains an important interdisciplinary problem in supportive oncology. Aims — to comparatively evaluate the clinical efficacy of the supportive treatment for acneiform rash induced by epidermal growth factor receptor inhibitors, including topical treatment with ivermectin cream and balneotherapy. Methods. In an open, prospective, randomized study, data from 114 patients with acneiform rash induced by monoclonal antibodies to EGFR were analyzed. All groups received intermittent supportive treatment according to a single regimen, continuous external therapy included: in group 1 — hypotonic thermal water, in group 2 — ivermectin 1% cream, in group 3 — hypotonic thermal water and ivermectin 1% cream. The observation period was 3 months. Acneiform rash severity was assessed using the CTCAE-NCI v5.0 criteria and a developed acneiform rash clinical severity scale. The intensity of subjective symptoms was assessed using a 10-point visual analog scale (VAS). The modified dermatological life quality index (mDLQI) was used to assess the impact of acneiform rash on patient’s quality of life. Results. A significant decrease in all of the studied parameters was observed in the groups by the end of the 1st week of supportive treatment and remained up to the end of the observation period (p < 0.05). There were no statistically significant differences between groups 2 and 3 with respect to the acneiform rash clinical severity scale, but their values were significantly lower than those of group 1 (group 1 vs. group 2, p < 0.001; group 1 vs. group 3, p < 0.001). The most rapid resolution of all subjective symptoms was observed in group 3. Significantly lower mDLQI values were also observed in group 3 starting from the 1st week of supportive treatment until the end of the follow-up period (р < 0.05). No severe adverse reactions were registered in any of the groups during the study. Conclusions. The developed regimens for the supportive treatment of acneiform rash have demonstrated a high efficacy in resolving papulopustular rash and associated subjective symptoms. The use of a complex approach including continuous topical therapy with ivermectin cream and hypotonic thermal water leads to the resolution of rash and relief of subjective symptoms in the shortest time, allows to safely maintain the achieved clinical effect for a long period of observation, has the most significant positive impact on the quality of life of cancer patients.

Full Text

Restricted Access

About the authors

Larisa S. Kruglova

Central State Medical Academy of Department of Presidential Affairs of the Russian Federation

Author for correspondence.
Email: kruglovals@mail.ru
ORCID iD: 0000-0002-5044-5265

MD, PhD, Professor

Россия, Moscow

Eugenia A. Shatokhina

Central State Medical Academy of Department of Presidential Affairs of the Russian Federation; Medical Center of M.V. Lomonosov Moscow State University

Email: e.a.shatokhina@gmail.com
ORCID iD: 0000-0002-0238-6563

MD, PhD, Assistant Professor

Россия, Moscow; Moscow

Aleksandra S. Polonskaia

Central State Medical Academy of Department of Presidential Affairs of the Russian Federation

Email: dr.polonskaia@gmail.com
ORCID iD: 0000-0001-6888-4760

MD, PhD

Россия, Moscow

References

  1. Seebacher NA, Stacy AE, Porter GM, et al. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019;38(1):156. doi: https://doi.org/10.1186/s13046-019-1094-2
  2. Федянин М.Ю., Гладков О.А., Гордеев С.С., и др. Практические рекомендации по лекарственному лечению рака ободочной кишки, ректосигмоидного соединения и прямой кишки // Злокачественные опухоли: Практические рекомендации RUSSCO. — 2022. — Т. 12. — № 3s2. — С. 401–454. [Fedyanin MY, Gladkov OA, Gordeev SS, et al. Practice guidelines for the drug treatment of cancer of the colon, rectosigmoid junction and rectum. Malignant Tumors: Practical Recommendations RUSSCO. 2022;12(3s2):401–454. (In Russ.)] doi: https://doi.org/10.18027/2224-5057-2022-12-3s2-401-454
  3. Лактионов К.К., Артамонова Е.В., Бредер В.В., и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого // Злокачественные опухоли: Практические рекомендации RUSSCO. — 2022. — Т. 12. — № 3s2. — С. 41–59. [Laktionov KK, Artamonova EV, Breder VV, et al. Practical guidelines for drug treatment of non-small cell lung cancer. Malignant Tumors: Practical Recommendations RUSSCO. 2022;12(3s2):41–59. (In Russ.)] doi: https://doi.org/10.18027/2224-5057-2022-12-3s2-41-59
  4. Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В., и др. Практические рекомендации по лечению злокачественных опухолей головы и шеи // Злокачественные опухоли: Практические рекомендации RUSSCO. — 2022. — Т. 12. — № 3s2. — С. 94–112. [Bolotina LV, Vladimirova LY, Dengina N.V., et al. Practical recommendations for the treatment of malignant head and neck tumors. Malignant Tumors: Practical Recommendations RUSSCO. 2022;12(3s2):94–112. (In Russ.)] doi: https://doi.org/10.18027/2224-5057-2022-12-3s2-94-112
  5. Полонская А.С., Шатохина Е.А., Круглова Л.С. Дерматологические нежелательные явления ингибиторов рецептора эпидермального фактора роста: современный взгляд на междисциплинарную проблему // Опухоли головы и шеи. — 2021. — Т. 4. — № 11. — С. 97–109. [Polonskaia AS, Shatokhina EA, Kruglova LS. Dermatologic adverse events associated with epidermal growth factor receptor inhibitors: current concepts of interdisciplinary problem. Head and Neck Tumors (HNT). 2021;11(4):97–109. (In Russ.)] doi: https://doi.org/10.17650/2222-1468-2021-11-4-97-109
  6. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56(2):317–326. doi: https://doi.org/10.1016/j.jaad.2006.09.005
  7. Boone SL, Rademaker A, Liu D, et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007;72(3–4):152–159. doi: https://doi.org/10.1159/000112795
  8. Королева И.А., Болотина Л.В., Гладков О.А., и др. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию // Злокачественные опухоли: Практические рекомендации RUSSCO. — 2022. — Т. 12. — № 3s2. — С. 101–122. [Koroleva IA, Bolotina LV, Gladkov AA, et al. Practice guidelines for the treatment of dermatological reactions in patients receiving antitumor drug therapy. Malignant Tumors: Practical Recommendations RUSSCO. 2022;12(3s2):101–122. (In Russ.)] doi: https://doi.org/10.18027/2224-5057-2022-12-3s2-101-122
  9. Lacouture ME, Sibaud V, Gerber PA, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆. Ann Oncol. 2021;32(2):157–170. doi: https://doi.org/10.1016/j.annonc.2020.11.005
  10. Шатохина Е.А., Круглова Л.С., Полонская А.С. Лечение акнеподобной сыпи, индуцированной моноклональными антителами к рецептору эпидермального фактора роста (EGFR) // Медицинский Совет. — 2020. — № 20. — С. 157–164. [Shatokhina E.A., Kruglova L.S., Polonskaia A.S. Management of acneiform rash associated with anti-EGFR monoclonal antibody treatment. Meditsinskiy sovet = Medical Council. 2020;20:157–164. (In Russ.)] doi: https://doi.org/10.21518/2079-701X-2020-20-157-164
  11. Gerber PA, Kukova G, Buhren BA, et al. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology. 2011;222(2):144–147. doi: https://doi.org/10.1159/000323001
  12. Lacouture ME. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. John Wiley & Sons; 2014. 440 p.
  13. Шатохина Е.А. Восстановительное лечение пациентов с дерматологическими нежелательными явлениями таргетной противоопухолевой терапии: дис. ... д-ра мед. наук. — М., 2020. — 321 с. [Shatokhina EA. Supportive treatment of patients with dermatological adverse events of targeted antitumor therapy: dissertation of the Doctor of Medical Sciences. Moscow; 2020. 321 p.]
  14. Ventre E, Rozières A, Lenief V, et al. Topical ivermectin improves allergic skin inflammation. Allergy. 2017;72(8):1212–1221. doi: https://doi.org/10.1111/all.13118
  15. Galliano MF, Bäsler K, Caruana A, et al. Protective effect of Aquaphilus dolomiae extract-G1, ADE-G1, on tight junction barrier function in a Staphylococcus aureus-infected atopic dermatitis model. J Eur Acad Dermatol Venereol. 2020;34(Suppl 5):30–36. doi: https://doi.org/10.1111/jdv.16516
  16. Zöller N, Valesky E, Hofmann M, et al. Impact of Different Spa Waters on Inflammation Parameters in Human Keratinocyte HaCaT Cells. Ann Dermatol. 2015;27(6):709–714. doi: https://doi.org/10.5021/ad.2015.27.6.709
  17. Eliasse Y, Redoules D, Espinosa E. Impact of Avène Thermal Spring Water on immune cells. J Eur Acad Dermatol Venereol. 2020;34(Suppl 5):21–26. doi: https://doi.org/10.1111/jdv.16335
  18. Common terminology criteria for adverse events (CTCAE) version 4.0 (May 28, 2009). US Department of Health and Human Services, et al.; National Institute of Health, National Cancer Institute, v. 4.03. 2010. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
  19. Отдельнова К.А. Определение необходимого числа наблюдений в социально-гигиенических исследованиях // Сб. трудов 2-го ММИ. — 1980. — Т. 150. — Вып. 6. — С. 18–22. [Otdelnova KA. Determination of the necessary number of observations in socio-hygienic research. Proceedings of the 2nd MMI. 1980;150:18–22. (In Russ.)]
  20. Гланц С. Медико-биологическая статистика. — М.: Практика, 1998. — 460 с. [Glantz S. Medico-Biological Statistics. Moscow: Praktika; 1998. 460 p. (In Russ.)]
  21. Crichtlow D. E., Fligner M.A. On distribution-free multiple comparisons in the one-way analysis of variance. Communications in Statistics —Theory and Methods. 1991;20(1):3739–3747. Available from: https://www.scinapse.io/papers/1969849879
  22. Bellini V, Bianchi L, Pelliccia S, et al. Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients. J Cutan Pathol. 2016;43(3):211–218. doi: https://doi.org/10.1111/cup.12630
  23. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–812. doi: https://doi.org/10.1038/nrc1970
  24. Henehan M, Montuno M, De Benedetto A. Doxycycline as an anti-inflammatory agent: updates in dermatology. J Eur Acad Dermatol Venereol. 2017;31(11):1800–1808. doi: https://doi.org/10.1111/jdv.14345
  25. Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337–352. doi: https://doi.org/10.1111/bph.12139
  26. Zargari O, Aghazadeh N, Moeineddin F. Clinical applications of topical ivermectin in dermatology. Dermatol Online J. 2016;22(9):13030/qt1kq4p7pp.
  27. Schaller M, Kemény L, Havlickova B, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82(2):336–343. doi: https://doi.org/10.1016/j.jaad.2019.05.063
  28. Lehen’kyi V, Vandenberghe M, Belaubre F, et al. Acceleration of keratinocyte differentiation by transient receptor potential vanilloid (TRPV6) channel activation. J Eur Acad Dermatol Venereol. 2011;25(Suppl 1):12–18. doi: https://doi.org/10.1111/j.1468-3083.2010.03894.x
  29. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). — М.: МНИОИ им. П.А. Герцена, 2022. — 252 с. [Kaprin AD, Starinsky VV, Shakhzadova AO. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow: Herzen Scientific Research Institute of Interventional Immunology; 2022. 252 p. (In Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Рис. 1. Акнеподобная сыпь 2-й степени тяжести (CTCAE-NCI v. 5.0) на фоне таргетной противоопухолевой терапии цетуксимабом

Download (184KB)
Indexing metadata
3. Рис. 2. Диаграмма CONSORT для описания диспозиции пациентов по результатам рандомизации в исследовании

Download (464KB)
Indexing metadata
4. Рис. 3. Сравнительный анализ эффективности схем восстановительного лечения в отношении разрешения папулопустулезных высыпаний по шкале тяжести акнеподобной сыпи, критерий Краскела–Уоллиса

Download (157KB)
Indexing metadata
5. Рис. 4. Сравнительный анализ эффективности схем восстановительного лечения акнеподобной сыпи по ВАШ зуда, критерий Краскела–Уоллиса

Download (153KB)
Indexing metadata
6. Рис. 5. Сравнительный анализ эффективности схем восстановительного лечения акнеподобной сыпи по ВАШ гиперчувствительности, критерий Краскела–Уоллиса

Download (134KB)
Indexing metadata
7. Рис. 6. Сравнительный анализ влияния разработанных схем восстановительного лечения акнеподобной сыпи на качество жизни онкологических пациентов по данным мДИКЖ, критерий Краскела–Уоллиса

Download (161KB)
Indexing metadata

Copyright (c) 2023 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies